Mirum Pharmaceuticals Files 8-K on Shareholder Vote Matters

TL;DR

Mirum Pharma held a shareholder vote, details to follow.

AI Summary

Mirum Pharmaceuticals, Inc. filed an 8-K on June 6, 2024, to report on matters submitted to a vote of its security holders. The filing indicates that the company held a meeting where security holders voted on certain proposals. Specific details of the proposals and their outcomes were not detailed in this initial filing.

Why It Matters

This filing signals that Mirum Pharmaceuticals held a shareholder meeting, which could involve significant corporate decisions or changes that impact investors.

Risk Assessment

Risk Level: low — This is a routine 8-K filing to report on a shareholder vote, with no immediate financial or operational changes disclosed.

Key Players & Entities

• Mirum Pharmaceuticals, Inc. (company) — Registrant
• June 5, 2024 (date) — Date of earliest event reported
• June 6, 2024 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation
• Foster City, California (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.0001 — ich registered Common stock, par value $0.0001 per share MIRM Nasdaq Global Market

Filing Documents

• mirm-20240605.htm (8-K) — 41KB
• 0001759425-24-000023.txt ( ) — 162KB
• mirm-20240605.xsd (EX-101.SCH) — 2KB
• mirm-20240605_lab.xml (EX-101.LAB) — 21KB
• mirm-20240605_pre.xml (EX-101.PRE) — 12KB
• mirm-20240605_htm.xml (XML) — 3KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On June 5, 2024, the Company held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). As of April 10, 2024, the record date for the Annual Meeting, 47,118,397 shares of common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below. Proposal 1. Election of Directors The Company's stockholders elected the three persons listed below as Class II directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results are as follows: Votes For Votes Withheld Broker Non-Votes Laurent Fischer, M.D. 19,162,293 14,762,966 3,790,601 Patrick Heron 24,363,371 9,561,888 3,790,601 Saira Ramasastry, MS, M.Phil. 25,853,444 8,071,815 3,790,601 Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors (the "Board") of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. The final voting results are as follows: Votes For Votes Against Abstentions 37,536,300 36,362 143,198 Proposal 3. Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement for the Annual Meeting. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 32,709,274 1,125,532 90,453 3,790,601 Proposal 4. Advisory Vote on the Frequency of Solicitation of Advisory Stockholder Approval of Executive Compensation The Company's stockholders indicated, on an advisory basis, that the preferred frequency of the stockholder advisory vote on the com

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Mirum Pharmaceuticals, Inc. Date: June 6, 2024 By: /s/ Christopher Peetz Christopher Peetz Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR